Deficiency of Primate-Specific TFDP3 Causes Male Infertility with Oligoasthenoteratozoospermia in Humans and Cynomolgus Monkeys

A primate-exclusive X-linked gene, TFDP3, was defective in 8 infertile men with OAT — and silencing it in monkeys replicated the phenotype

Journal: Science China. Life Sciences | Published: 2026-01-27 | Type: Journal Article | PMID: 41634254 Authors: Liu Chunyu, Tu Chaofeng, Li Peng et al. (multiple Chinese reproductive medicine and stem cell centers) Funding/COI: Funding not listed. Authors declare no conflict of interest.

Summary

TFDP3 is a gene found only in primates, expressed heavily in the testis, and until now largely unstudied in human fertility. Using whole-exome sequencing across infertile men, this team found damaging variants in TFDP3 in 8 men, all presenting with oligoasthenoteratozoospermia — low count, poor motility, abnormal morphology. They then knocked the gene down in cynomolgus monkeys and watched the same sperm phenotype emerge, implicating TFDP3 loss in triggering E2F1-driven apoptosis in developing sperm cells.

Claims

• Deleterious TFDP3 variants identified in 8 men with OAT via whole-exome sequencing
• All 8 showed dramatically reduced sperm concentration, motility, and abnormal morphology
• Tfdp3 knockdown in male cynomolgus monkeys reproduced reduced sperm concentration, motility, and morphological defects
• Mechanistic finding: TFDP3 deficiency activates E2F1-induced apoptosis, reducing sperm count and motility
• 5 of 8 couples underwent ICSI and achieved pregnancy

Study Quality

The human genetic cohort is tiny — 8 men — which limits any statistical inference about prevalence or penetrance. Whole-exome sequencing without a well-matched population-level control database can overattribute variants as causal; the paper does not describe the frequency of these variants in gnomAD or equivalent population cohorts, which is a meaningful gap. The primate knockdown model strengthens the causal claim substantially: finding the same phenotype in a non-human primate after deliberate gene silencing is more persuasive than a human genetic association alone. The proposed mechanism (TFDP3 normally suppressing E2F1-mediated apoptosis in spermatocytes) is biologically coherent and supported by functional data, but the mechanistic work is described in the abstract only, and its depth cannot be evaluated without the full paper.

Red Flags

• n=8 men — extremely small; single-gene variants in this few patients cannot establish population-level pathogenicity without replication
• Funding source not disclosed — provenance of research support is unknown
• All cohorts are Chinese reproductive medicine centers; findings may not generalize across populations
• ICSI pregnancy rate (5/8) is reported as a positive signal but is effectively uncontrolled anecdote; couples undergoing ICSI for OAT from any cause succeed at similar rates
• Abstract does not report allele frequencies for identified TFDP3 variants relative to gnomAD or comparable databases

Strengths

• Non-human primate model provides cross-species validation — stronger than mouse models for a primate-specific gene that has no rodent ortholog
• X-linkage of TFDP3 makes biological sense: hemizygous males would show full loss-of-function from a single damaging allele, consistent with the phenotype
• Mechanistic pathway (E2F1 apoptosis axis) identified, not just a genetic association
• Multi-center sample for an 8-patient cohort (multiple IRBs, multiple hospitals)
• First study to characterize TFDP3's role in spermatogenesis with in vivo evidence

Verdict

This is a plausible, interesting discovery — a primate-specific gene with no rodent model that required a monkey knockdown to validate, and it delivered. The science is internally consistent and the primate model is the right tool for a primate-specific gene. But 8 patients is 8 patients. This paper belongs in the "interesting lead" category, not the "established cause" column. It expands the genetic diagnostic panel for OAT in principle; whether TFDP3 sequencing belongs in clinical workups depends entirely on replication in larger cohorts that haven't yet been published.